KVUE

LONGINSIDER SELL

KENVUE INC

Funds

Score

4.25

vs SPY

-14.9%

Stock return (since Q-end)

+1.4%

SPY return (since Q-end)

+16.3%

Current price

$17.28

News Summary

Neutral

Kenvue delivered a strong Q1 2026 EPS beat (+47% YoY to $0.32) with margin expansion and operational momentum, but the pending Kimberly-Clark acquisition dominates the investment narrative with suspended guidance and limited near-term upside. Key regulatory approvals (U.S. HSR, India CCI) are secured, positioning the deal for H2 2026 close, though unresolved legal risks around Tylenol and talc products remain material headwinds.

Red flags

•Guidance suspended due to pending M&A, limiting visibility
•Stock trading near implied deal value ($18.20 consensus target) with downside risk if transaction fails
•Ongoing legal exposure from Tylenol marketing and talc/acetaminophen litigation flagged as key risks
•Q1 revenue slightly missed consensus ($3.909B vs. $3.919B estimate)
•Aggressive $250M restructuring with 3.5% workforce reduction underway, execution risk

Funds Buying (3)

Fund	Manager	Shares Held	∆ Shares	Position Value	QoQ	Status
Soros Fund Management	Soros Family Office	3.2M	+1.9M	$54.4B	+153%	Existing
Point72	Steve Cohen	461K	+461K	$8.0B	—	NEW
Maverick Capital	Lee Ainslie	92K	+92K	$1.6B	—	NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter.

Insider Activity

Name	Title	Type	Shares	Price	Value	Filed
Orlando Matthew	General Counsel	SELL	38K	$17.66	$0.68M	2026-05-08